SEK 4.2 million grant to Hans Lennernäs and Johan Lennartsson

2021-11-23

Hans Lennernäs and Johan Lennartsson, Professors at the Faculty of Pharmacy, receive a total of SEK 4.2 million when the Swedish Cancer Foundation allocates funding for research projects with the greatest potential to contribute to defeating cancer.

Hans Lennernäs och Johan Lennartsson
Hans Lennernäs and Johan Lennartsson, the Faculty of Pharmacy

The Swedish Cancer Foundation allocates SEK 4.2 million to research projects at Uppsala University’s Faculty of Pharmacy. Hans Lennernäs, Professor of Biopharmacy, is awarded SEK 2.4 million for the continued development of fat-based particles that are loaded with chemotherapy drugs and then search for cancerous tumors in the liver.

“The increase in liver cancer may be due to more widespread body obesity in the population, as fat is stored in the liver and causes an inflammation that can lead to the development of liver cancer. Our method is based on using small fat particles that for a while are stored in the liver and deliver chemotherapy. Hopefully the effects will be greater and the side effects less with such local and advanced treatment, says Hans Lennernäs.

Johan Lennartsson, Professor of Pharmaceutical Cell Biology, receives SEK 1.8 million for the project Studies on cross-talk between steroid receptors and receptor tyrosine kinases in cancer development. Both grants will be allocated over three years.

Facts

  • The Swedish Cancer Foundation funds Swedish research projects judged to have the greatest potential to contribute to defeating cancer.
  • The 2021 funding was the largest to date from the Swedish Cancer Foundation.

More information

Contact

Johan Lennartsson, Professor of Pharmaceutical Cell Biology
Dep. of Pharmaceutical Biosciences
johan.lennartsson@farmbio.uu.se

Hans Lennernäs, Professor of Biopharmacy
Dep. of Pharmaceutical Biosciences
hans.lennernas@farmbio.uu.se

text: Magnus Alsne, photo: Mikael Wallerstedt

More news

Last modified: 2021-11-05